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Abstract
Objective—Occupational exposure to indium compounds including indium-tin oxide (ITO) can 
result in potentially fatal indium lung disease. We compared plasma, serum and whole blood 
indium concentrations (InP, InS and InB) from workers at a single ITO production facility to assess 
the comparability of these matrices used for biological monitoring of indium exposure.
Method—InP, InS and InB were measured using inductively coupled mass spectrometry from 
consenting workers at an ITO production facility with specimen collection occurring during June–
July 2014. Matched pairs from workers were assessed to determine the matrix relationships using 
the Pearson correlation, paired t-tests, per cent difference, linear regression and κ statistics.
Results—Indium matrices were collected from 80 workers. Mean (SD) InP, InS and InB were 
3.48 (3.84), 3.90 (4.15) and 4.66 (5.32) mcg/L, respectively. The InS–InP difference was 14%; InS 
was higher in all but two workers. InP and InS were highly correlated (r=>0.99). The InB–InS 
difference was 19%; InB was higher in 85% of workers. The InB–InP difference was 34%; InB was 
higher in 66% of workers. InB was highly correlated with both InP and InS (r=0.97 and 0.96, 
respectively). κ Statistics were 0.84, 0.83 and 0.82 for InP, InS and InB, respectively, for 
individuals with each matrix ≥1 mcg/L (p<0.01).
Conclusions—While all matrices were highly correlated, we encourage the use of InP and InS to 
reliably compare studies across different populations using different matrices. The higher per cent 
difference and increased variability of InB may limit its utility in comparisons with InP and InS in 
different populations.
Occupational exposure to indium compounds including indium-tin oxide (ITO) can result in 
potentially fatal indium lung disease. The spectrum of disease includes pulmonary alveolar 
proteinosis that may progress to fibrosis with or without emphysema.1 Biological 
monitoring of indium using plasma, serum or blood has served as the foundation to assess 
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exposure and prevent adverse health effects in workers exposed to ITO and other indium 
compounds. However, as there are no reference values for indium in these matrices, the 
extent to which the selected matrix affects the measurements is unknown.
Exposure to indium is rare and likely occupational in nature when it occurs. However, 
knowledge of the absorption, distribution and elimination of indium in the human body is 
limited. The fate of inhaled indium in the body is likely influenced by the chemical form and 
duration of exposure.2 Ionic indium that is absorbed into the blood may bind to blood 
proteins. In one study, the estimated biological half-life of indium in serum was 8.1 years for 
workers who had quit handling indium for >3 years, but the half-life varied and was longer 
for those with a higher initial indium burden.3 Another study has shown that former workers 
had similar levels of indium in the serum as current workers an average of nearly 5 years 
since exposure to indium, suggesting indium in the blood represents cumulative exposure 
with an extended half-life.4
To date, epidemiological studies have measured indium concentrations in plasma (InP) or 
serum (InS) to evaluate worker exposure to indium. Results of these studies have been used 
to establish recommendations and for regulation. In the USA, adverse health outcomes were 
associated with ≥1 mcg/L InP.5 In Japan, a biological exposure limit of 3 mcg/L InS has 
been established.6 Other countries, including Germany and Korea, are also considering 
developing standards. Whole blood indium (InB) has been used in the clinical setting to 
monitor indium exposure. Yet the equivalence of these different matrices has not been 
evaluated. To assess comparability of these matrices, we analysed InP, InS and InB from 
workers at a single ITO production facility measured during a narrow timeframe.
METHODS
As part of a longitudinal research study approved by the Institutional Review Board of the 
National Institute for Occupational Safety and Health (NIOSH), InP and InS were collected 
from consenting workers at an ITO production facility during June–July 2014. Separately, 
InB was measured during June–July 2014 as part of the company’s medical surveillance 
programme, and results were provided to NIOSH with study participants’ permission.
All measurements were performed by one commercial laboratory using inductively coupled 
plasma mass spectrometry. For InP and InS, the indium analytical method had a limit of 
detection (LOD) of 0.03 mcg/L and a limit of quantification (LOQ) of 0.1 mcg/L. InP and 
InS values between the LOD and LOQ were reported by the laboratory. For InB, the LOD 
was not available and the LOQ was 0.5 mcg/L. Values below the LOQ were not reported by 
the laboratory.
We compared matched pairs from workers for each matrix. For comparison to InB, we 
selected only those who had InB levels greater than its LOQ. We analysed the subset of 
workers with each matrix collected in order to assess all three substrates together. We 
measured matrix agreement for identifying individuals with InP, InS and InB ≥1 mcg/L. We 
stratified the mean differences of InB–InP and InB–InS by ≥6 days and <6 days between 
specimen collection times. Matrix relationships were evaluated using the Pearson 
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correlation, paired t-tests, per cent difference, linear regression and κ statistics using JMP 
software V.10.0.1 (SAS Institute, Cary, North Carolina, USA). p Values reported are two 
sided. We considered p≤0.05 to be significant.
RESULTS
Indium matrices were collected from 80 workers at the ITO production facility during June–
July 2014. Of these workers, 86% were men. Sixty-six per cent were white, 8% were black 
and 10% were Asian; 16% were Hispanic. Median age was 45 years (range: 19–66 years). 
Median tenure at the ITO facility was 3.4 years (range: 0.1–38 years). Our analyses included 
76 workers (95%) with InP and InS measured, 53 (66%) with InP and InB measured and 50 
(63%) with InS and InB measured. After removing those without each matrix measured 
(n=12) and those with InB below an LOQ of 0.5 mcg/L (n=18), 50 workers were included in 
the analyses comparing InP, InS and InB. For those individuals with each matrix measured, 
whole blood was collected at a median of 5.6 days before simultaneous plasma and serum 
collection, with whole blood collection ranging from 20 days before to 34 days after plasma 
and serum collection.
Mean (SD) InP, InS and InB were 3.48 (3.84), 3.90 (4.15) and 4.66 (5.32) mcg/L, 
respectively, for the 50 workers with each exposure matrix collected. The InS–InP difference 
was 14% on average, with individual matched pairs ranging from −0.02 to 2 mcg/L 
difference; InS was higher than InP in all but two workers. InP and InS were highly correlated 
(r=>0.99) (figure 1A). InB was more variable when compared with both InP and InS. The 
InB–InS difference was 19% on average (range: −0.70 to 10 mcg/L difference); InB was 
higher in 85% of workers. The InB–InP difference was 34% on average (range: −0.21 to 11 
mcg/L difference); InB was higher in 66% of workers. InB was highly correlated with both 
InP and InS (r=0.97 and 0.96, respectively) (figure 1B, C). κ Statistics were 0.84, 0.83 and 
0.82 for InP and InS, InP and InB and InS and InB, respectively, for individuals with each 
matrix ≥1 mcg/L (p<0.01). The InB–InP and InB–InS mean differences were not significantly 
different in workers with specimen collection occurring ≥6 days and <6 days apart (0.84 and 
1.47 mcg/L (p=0.22); 0.33 and 1.10 mcg/L (p=0.11), respectively).
DISCUSSION
Our study comparing indium in plasma, serum and blood of workers from a single facility 
during a narrow timeframe is the first to the best of our knowledge characterising 
relationships among these three matrices. While InP, InS and InB were highly correlated, we 
found meaningful differences that should be considered before comparing indium exposures 
estimated using different matrices.
On average, InP and InS had the smallest relative difference of 14%. Seventy-four per cent 
(97%) of the 76 workers had higher InS than InP, suggesting InP and InS could be reliably 
used when comparing indium exposures. Owing to the higher per cent difference and 
variability, InB may not be as useful for comparisons to either InP or InS in different 
workforces using the different matrices. InB was 34% higher than InP on average; however, 
in more than one-third (34%) of workers InB was lower than InP, InB shared a similar 
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relationship with InS, with InB being 19% higher on average, but lower in 15% of workers. 
This is consistent with a 2003 study by Miyaki et al7 comparing biological monitoring of 
indium using blood, serum and urine in which mean InB was higher than InS. Agreement 
statistics between each matrix were high. Individuals with InP ≥1 mcg/L, a value associated 
with adverse health outcomes,5 generally had InS and InB ≥1 mcg/L, suggesting each matrix 
could be used to detect overexposure to indium.
There are several plausible explanations for indium measuring slightly higher in serum than 
plasma. InP was measured using trace metal-free specimen collection tubes. It is possible 
that the higher mean InS we observed was due to positive interference during analysis by 
elements contained in serum collection tubes. Specimen collection and storage can interfere 
with trace metal measurement.8 An effect of sample concentration may also account for the 
higher indium measured in serum than plasma. Fibrinogen is the principal component 
present in plasma but removed from serum during coagulation.9 As it lacks fibrinogen, 
serum is more concentrated than plasma, making it possible that InS has a higher mean due 
to the smaller volume fraction in serum than in plasma.
The higher mean and increased variability of InB compared with both InP and InS are likely 
multifactorial. In addition to the potential issue of elements contained in the collection tubes 
described above, these differences could involve interaction between indium compounds and 
the cellular compartment of blood consisting predominantly of red blood cells. However, the 
higher mean InB is consistent with a recent study in which 9 (82%) of the 11 metals and 
trace elements were more concentrated in the whole blood than in the serum.10 Other factors 
that could contribute to variability include varying sampling times, and that different 
instruments with different sensitivities were used. We believe these factors would not 
substantially affect our results. Most samples were collected during the same week and 
indium levels in these matrices are indicative of long-term exposure and unlikely to fluctuate 
during our study window.11 When we compared the InB–InP and InB–InS mean differences 
in workers with sample collection occurring ≥6 days and <6 days apart, we found no 
significant differences, providing further evidence that sample collection time had limited 
influence on the results. Moreover, by excluding InB values below the LOQ in our analyses, 
the different sensitivities of the instruments unlikely contributed much to variability. 
Nonetheless, the possibility remains that some of the observed differences reflect when and 
how blood samples were collected and analysed. Ultimately, further investigation into the 
absorption, distribution and elimination of inhaled indium compounds may provide a clearer 
explanation for these differences.
The small sample size precluded the development of correction factors that could be used to 
adjust concentrations and allow accurate comparisons across populations. However, a factor 
to account for the consistently higher fraction of indium identified in the serum compared 
with plasma may be possible with additional data from different workplaces. Likewise, a 
larger sample size from different workplaces is needed to develop a reliable correction factor 
for whole blood compared with both plasma and serum, particularly given the variability of 
indium measured in whole blood compared with the other matrices in our study. While 
environmental health studies increasingly are quantifying certain metals using various 
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matrices in different populations,1012 it is unlikely that reference values will be established 
for indium as it is not an essential trace element.
InP, InS and InB have been used clinically and/or for epidemiological studies to assess 
exposure to indium. We measured these matrices that are currently used for biological 
monitoring in a single workplace during a narrow timeframe. While all three matrices were 
highly correlated, our study suggests InP and InS can be used to reliably compare studies 
across different populations. While InB may have value in clinical settings to serially 
monitor indium exposure of an individual, the higher per cent difference and increased 
variability measured in this ITO production facility workforce imply limited utility in 
comparisons with InP and InS in different populations using these different matrices.
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What this paper adds
• Indium in plasma, serum and whole blood has been used for biological 
monitoring of indium exposure in epidemiological studies and/or clinical 
settings. As there are no reference values for indium in these matrices, the 
extent to which the selected matrix affects the measurements is unknown.
• While InP, InS and InB were highly correlated, we conclude InP and InS are 
suitable to reliably compare studies across different populations. Owing to the 
higher per cent difference and increased variability of InB relative to InP and 
InS in this population, we would urge caution in comparing InB to InP or InS.
• As countries have either already established or are considering standards to 
limit exposure to indium in occupational settings, our paper helps determine 
the relationship of different blood matrices used for biological monitoring of 
indium exposure.
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Blood matrices scatterplots with linear regression lines: (A) InP and InS (N=76), (B) InP and 
InB (N=53) and (C) InS and InB (N=50). InB, blood indium; InP, plasma indium; InS, serum 
indium.
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